GeoVax Labs (NASDAQ:GOVX) Given Buy Rating at HC Wainwright

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 143.90% from the stock’s previous close.

GeoVax Labs Stock Up 3.0 %

GOVX opened at $3.28 on Tuesday. The firm’s fifty day moving average price is $1.79 and its 200 day moving average price is $2.70. GeoVax Labs has a 12-month low of $1.09 and a 12-month high of $10.24.

GeoVax Labs (NASDAQ:GOVX) last issued its earnings results on Tuesday, May 14th. The company reported ($2.47) EPS for the quarter. As a group, research analysts predict that GeoVax Labs will post -7.41 EPS for the current year.

Institutional Investors Weigh In On GeoVax Labs

A hedge fund recently bought a new stake in GeoVax Labs stock. Armistice Capital LLC bought a new stake in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned approximately 91.38% of GeoVax Labs at the end of the most recent reporting period. 6.09% of the stock is currently owned by institutional investors and hedge funds.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.